Pentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines

Annals of Clinical and Laboratory Science

Volumn 34, Issue 4, 2004, Pages 427-436

  Ji, Qing ^a   Zhang, Lidong ^a   Jia, Hongbin ^a   Yang, Jianjun ^a   Xu, Jianguo ^a  

^a JINLING HOSPITAL   (China)

Author keywords

Interleukin 10; Interleukin 6; NF B; Pentoxifylline; TNF

Indexed keywords

CYTOKINE; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; IN VIVO STUDY; INFLAMMATION; INTESTINE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACTIVATION; PROTEIN INDUCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPSIS;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDOTOXEMIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; INJECTIONS, INTRAVENOUS; INTERLEUKIN-10; INTERLEUKIN-6; JEJUNUM; LIPOPOLYSACCHARIDES; MALE; NF-KAPPA B; PENTOXIFYLLINE; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

ANIMALIA;

EID: 11144300239     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Sriskandan S, Cohen J. Gram-positive sepsis: Mechanism and differences from gram-negative sepsis. Infect Dis Clin North Am 1999;13:397-412.
2. Feezor RJ, Oberholzer C, Baker HV, Novick D, Rubinstein M, Moldawer LL, Pribble J, Souza S, Dinarello CA, Ertel W, Oberholzer A. Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria. Infect Immun 2003;71:5803-5813.
3. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150.
4. Calandra T. Pathogenesis of septic shock: implications for prevention and treatment. J Chemother 2001;13(Spec No 1):173-180.
5. Hoffman WD, Natanson C. Endotoxin in septic shock. Anesth Analg 1993;77:613-624.
6. Tan XD, Wang H, Gonzalez-Crussi FX, Chang H, Gonzalez-Crussi F, Hsueh W. Platelet activating factor and endotoxin increase the enzyme activity and gene expression of type II phospholipase A2 in the rat intestine. Role of polymorphonuclear leukocytes. J Immunol 1996;156:2985-2990.
7. Wang Q, Wang JJ, Boyce S, Fischer JE, Hasseigren PO. Endotoxemia and IL-1 beta stimulate mucosal IL-6 production in different parts of the gastrointestinal tract. J Surg Res 1998;76:27-31.
8. Parikh AA, Salzman AL, Fischer JE, Szabo C, Hasselgren PO. Interleukin-1 beta and interferon-gamma regulate interleukin-6 production in cultured human intestinal epithelial cells. Shock 1997;8:249-255.
9. Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, Strandness E. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982;104:66-72.
10. Stricter RM, Remick DG, Ward PA, Spengle RN, Lynch JP, Larrick J, Kunkel SL. Cellular and molecular regulation of TNF-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230-1236.
11. Zabel P, Schonharting MM, Woher DT Schade UF. Oxpentifylline in endotoxaemia. Lancet 1989;2:1474-1477.
12. Schandene L, Vandenbussche P, Crusiaux A, Alegre ML, Abramowicz D, Dupont E, Content J, Goldman M. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) by monocytes and T cells. Immunology 1992;76:30-34.
13. Bienvenu J, Coulon L, Barbier Y, Doche C, Lepape A, Guenounou M. Study of pentoxifylline of TNF-α and interleukin-6 secretion in healthy and septic patients by the use of an ex-vivo model on whole blood. Nouv Rev Fr Hematol 1992;34:65-67.
14. D'Hellencourt CL, Diaw L, Cornillet P, Guenounou M. Differential regulations of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int J Immunopharm 1996;18:739-748.
15. Cavaillon JM, Munoz C, Fitting C, Misset B, Carlet J. Circulating cytokines: the tip of the iceberg? Circ Shock 1992;38:145-152.
16. Keogh C, Fong Y, Marano MA, Seniuk S, He W, Barber A, Minei JP, Felsen D, Lowry SF, Moldawer LL. Identification of a novel tumor necrosis factor alpha/cachectin from the livers of burned and infected rats. Arch Surg 1990;125:79-84.
17. Wang Q, Meyer TA, Boyce ST, Wang JJ, Sun X, Tiao G, Fischer JE, Hasselgren PO. Endotoxemia in mice stimulates production of complement C3 and serum amyloid A in mucosa of small intestine. Am J Physiol 1998;275:R1584-1592.
18. Wang Q, Wang JJ, Fischer JE, Hasselgren PO. Mucosal production of complement C3 and serum amyloid A is differentially regulated in different parts of the gastrointestinal tract during endotoxemia in mice. J Gastrointest Surg 1998;2:537-546.
19. Meyer TA, Wang J, Tiao GM, Ogle CK, Fischer JE, Hasselgren PO. Sepsis and endotoxemia stimulate interleukin-6 production. Surgery 1995;118:336-342.
20. Magnotti, LJ, Upperman, JS, Xu D-Z, Lu Q; Deitch, EA. Gut-derived mesenteric lymph but not portal blood increases endothelial cell permeability and promotes lung injury after hemorrhagic shock. Ann Surg 1998;228:518-527.
21. Sambol JT Xu DZ, Adams CA, Magnotti LJ, Deitch EA. Mesenteric lymph duct ligation provides long term protection against hemorrhagic shock-induced lung injury. Shock 2000;14:416-419.
22. Deitch EA. Role of the gut lymphatic system in multiple organ failure. Curr Opin Crit Care 2001;7:92-98.
23. Langkamp HB, Donovan TB, Pate LM, Maull CD, Kudsk KA. Increased intestinal permeability following shock and penetrating trauma. Crit Care Med 1995;23:660-664.
24. Hasselgren PO. The significance of intestinal cytokines. In Cytokines and the Abdominal Surgeon (Schein M, Wise L, Eds), Landes, Austin, TX, 1998; pp 197-213.
25. Gullo A, Berlot G. Ingredients of organ dysfunction or failure. World J Surg 1996;20:430-436.
26. Nieuwenhuijzen GA, Goris RJ. The gut: the 'motor' of multiple organ dysfunction syndrome? Curr Opin Clin Nutr Metab Care 1999;2:399-404.
27. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Ann Rev Immunol 1996;14:649-683.
28. Jilg S, Barsig J, Leist M, Kusters S, Volk HD, Wendel A. Enhanced release of interleukin-10 and soluble tumor necrosis factor receptors as novel principles of methyl-xanthine action in murine models of endotoxic shock. J Pharmacol Exp Ther 1996;278:421-431.
29. Benbernou N, Esnault S, Shin HC, Fekkar H, Guenounou M. Differential regulation of IFN-gamma, IL-10 and inducible nitric oxide synthase in human T cells by cyclic AMP-dependent signal transduction pathway. Immunology 1997;91:361-368.
30. Shimada T, Watanaba N, Ohtsuka Y, Endoh M, Kojima K, Hiraishi H, Terano A. Polaprezine downregulates proinflammatory cytokine-induced nuclear factor-κB activation and interleukin-8 expression in gastric epithelial cells. J Pharmacol Exp Ther 1999;291:345-352.
31. Sun J, Li F, Chen J, Xu J. Effect of ketamine on NF-kappa B activity andTNF-alpha production in endotoxin-treated rats. Ann Clin Lab Sci 2004;34:181-186.
32. Beishuizen A, Vermes I, Haanen C. Endogenous mediators in sepsis and septic shock. Adv Clin Chem 1998;33:55-131
33. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 1988;57:505-518.
34. Old LJ. Tumor necrosis factor: another chapter in the long history of endotoxin. Nature 1987;330:602-603.
35. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986;320:584-588.
36. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr, Cerami A, Shires GT, Lowry SF. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988;166:147-153.
37. Wang Q, Fischer JE, Hasseigren PO. Treatment of endotoxemic mice with anti-interleukin-6 antibody paradoxically increases interleukin-6 levels and stimulates musosal protein synthesis. Arch Surg 1997;132:82-88.
38. Gauldie J, Richards C, Baumann H. IL-6 and the acute phase reaction. Res Immunol 1992;143:755-759.
39. Ohzato H, Yoshizaki K, Nishimoto N, Ogata A, Tagoh H, Monden M, Gotoh M, Kishimoto T, Mori T. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery 1992;111:201-209.
40. Beg AA, Finco PV, Nantermet TS, Baldwin AS Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol 1993;13:3301-3310.
41. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996;87:13-20.
42. Blackwell TS, Christman JW. The role of nuclear factor kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997;17:3-9.
43. Deitch EA, Morrison J, Berg R, Specian RD. Effect of hemorrhagic shock on bacterial translocation, intestinal morphology, and intestinal permeability in conventional and antibiotic-decontaminated rats. Crit Care Med 1990;18:529-536.
44. Deitch EA, Xu D, Franko L, Ayala A, Chaudry IH. Evidence favoring the role of the gut as a cytokine-generating organ in rats subjected to hemorrhagic shock. Shock 1994;1:141-146.
45. DeWaal MR, Abrams J, Bennett B, Figdor CG, deVries JE. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220.
46. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T-helper cell IV Th2 clones secrete a factor that inhibits cytokine production by ThI clones. J Exp Med 1989;170:2081-2095.
47. Howard M, O'Garra A. Biological properties of interleukin-10. Immunol Today 1992;13:198-200.
48. Liu SF, Ye X, Malik AB. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation 1999;100:1330-1307.